We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

167 hedge funds and large institutions have $390M invested in Arbutus Biopharma in 2025 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 46 increasing their positions, 52 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 9

37% more call options, than puts

Call options by funds: $3.1M | Put options by funds: $2.26M

15% more capital invested

Capital invested by funds: $340M → $390M (+$49.8M)

9% more funds holding

Funds holding: 153 → 167 (+14)

3.45% more ownership

Funds ownership: 54.92% → 58.38% (+3.5%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

12% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 52

Holders
167
Holders Change
+14
Holders Change %
+9.15%
% of All Funds
2.24%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
25
Increased
46
Reduced
52
Closed
9
Calls
$3.1M
Puts
$2.26M
Net Calls
+$835K
Net Calls Change
+$778K

Top Buyers

Rank Fund Capital Flow
1
FC
Foursixthree Capital
New York
+$8.17M
2
WP
Woodline Partners
California
+$5.62M
3
Goldman Sachs
Goldman Sachs
New York
+$5.15M
4
Morgan Stanley
Morgan Stanley
New York
+$4.02M
5
TSC
Two Seas Capital
New York
+$2.42M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$2.21M
2
JP Morgan Chase
JP Morgan Chase
New York
-$1.19M
3
BlackRock
BlackRock
New York
-$570K
4
Squarepoint
Squarepoint
New York
-$536K
5
LP
LMR Partners
United Kingdom
-$517K
Name Holding Trade Value Shares
Change 		Change in
Stake
AF
151
Allworth Financial
California
$2.26K +$2.26K +677 New
HIA
152
Harbor Investment Advisory
Maryland
$1.75K – – –
NA
153
NewEdge Advisors
Louisiana
$1.75K +$1.67K +500 New
SCM
154
Sterling Capital Management
North Carolina
$1.13K -$417 -125 -28%
PMAM
155
Picton Mahoney Asset Management
Ontario, Canada
$1K -$23.5K -7,059 -97%
Daiwa Securities Group
156
Daiwa Securities Group
Japan
$1K – – –
HFS
157
Hantz Financial Services
Michigan
$1K – – –
CCM
158
Coldstream Capital Management
Washington
$992 +$947 +284 New
LC
159
Lindbrook Capital
California
$991 – – –
PWA
160
Physician Wealth Advisors
Utah
$988 +$944 +283 New
FFA
161
Farther Finance Advisors
California
$926 -$25.8K -7,734 -97%
PWMG
162
Private Wealth Management Group
New Jersey
$845 – – –
PS
163
Principal Securities
Iowa
$752 – – –
LWCFA
164
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$648 +$667 +200 New
GI
165
GAMMA Investing
California
$443 -$200 -60 -32%
EWA
166
EverSource Wealth Advisors
Alabama
$286 +$273 +82 New
IA
167
IFP Advisors
Florida
$199 – – –
PWAM
168
Private Wealth Asset Management
Iowa
$178 +$170 +51 New
LP
169
LMR Partners
United Kingdom
– -$517K -158,249 Closed
BP
170
Ballentine Partners
Massachusetts
– -$102K -31,121 Closed
CC
171
Centiva Capital
New York
– -$100K -30,724 Closed
EAM
172
Exome Asset Management
New York
– -$92.5K -28,300 Closed
VEA
173
Virtus ETF Advisers
New York
– -$65.3K -19,970 Closed
TSS
174
Two Sigma Securities
New York
– -$63.7K -19,475 Closed
EFM
175
E Fund Management
China
– -$34K -10,385 Closed
4 5 6
7
8

ABUS Hedge Fund Activity: Q1 2025 in Review

167 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2025, worth a combined $390M — up 15% from $340M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ABUS positions and 9 closed out — a net gain of 16 holders — while 46 added to existing stakes and 52 trimmed.

The largest buyer was Foursixthree Capital, opening a new position worth an estimated $8.17M. The largest seller was State Street, cutting an estimated $2.21M.

  • 167 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2025, up from 153 in Q4 2024.
  • Funds reported $390M of Arbutus Biopharma stock for Q1 2025, up 15% quarter-over-quarter.
  • 25 funds opened new Arbutus Biopharma positions in Q1 2025 and 9 closed out, a net change of +16 holders.
  • The largest Arbutus Biopharma buyer in Q1 2025 was Foursixthree Capital, an estimated $8.17M added.
  • The largest Arbutus Biopharma seller in Q1 2025 was State Street, an estimated $2.21M sold.

Based on aggregated 13F filings for Q1 2025.